Maia Biotechnology Inc. held its Annual Meeting of stockholders on May 22, 2025. Stockholders re-elected Jean-Manassé Theagène and Stan V. Smith as Class III directors. The appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to increase the authorized common stock from 70,000,000 shares to 150,000,000 shares was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.